Navigation Links
Ennaid Therapeutics Prioritizes Zika Virus Rapid Drug Development in Wake of Crisis
Date:2/14/2016

ALPHARETTA, Ga., Feb. 14, 2016 /PRNewswire/ -- Ennaid Therapeutics, located in Alpharetta, GA is developing therapeutic cures to help the millions of people worldwide when infected with the mosquito-borne disease, Zika Virus, now named a global public health emergency by the World Health Organization and the CDC. The global health community is urging caution and care in response to Zika's explosive spread and is calling for rapidly stepped up efforts by researchers to find therapeutics and vaccines for those who contract it.

For years, Ennaid Therapeutics has been committed to developing cures for mosquito-borne diseases, including Dengue, Chikungunya and Zika viruses – and is now advancing its work on Zika to address the urgent global need.

Zika Virus

Zika is linked to microcephalic birth defects and possible eye damage in babies. The virus, which is transmitted by Aedes species mosquito, has infected 1 million Brazilians and 50+ people in the United States. An estimated 4 million infections are expected in the Americas in 2016. Zika's risk to pregnant women is a top priority, according to the CDC.

"Zika virus, which is now our focus, has been in our ten-product pipeline for years, and we will continue developing cures for the growing numbers of Dengue, West Nile and Chikungunya sufferers, among other mosquito-borne diseases," says Darnisha Harrison, Ennaid Therapeutics' CEO.

Please see link below of Discovery Channel's "Innovations with Ed Begley, Jr.", in which Ennaid Therapeutics will be featured: http://www.prweb.com/releases/2015/10/prweb13028491.htm.

Ennaid Therapeutics' Science

  • Our peptide fusion inhibitors show significant inhibition against many Flaviviridae family of viruses, such as Dengue and possibly Zika; both carried by the Aedes species mosquito, and both of the flavivirus genus
  • Our peptide's stem mimic the stem of many Flaviviridae viruses, thus inhibiting viral infections
  • Zika stem is a very close match to our peptide's stem and  feasibility studies are underway.
  • Already planned development studies will determine our peptide's inhibition against Zika virus in vivo and safety in pregnancy
  • Our fast-track development strategy will then allow Ennaid Therapeutics to immediately begin clinical trials, as funding is secured
  • Currently there are safe and effective commercialized peptide fusion inhibitors, such as Enfuvirtide, brand name Fuzeon

Ennaid Therapeutics

Founded in 2012, Ennaid Therapeutics is developing a proprietary platform technology of flavivirus fusion inhibitors that show significant inhibition against flavivirus infectivity, such as Dengue, et al. Their rapid development plan has the potential to safely and quickly bring a Zika virus therapeutic cure to market in record time.

Darnisha Harrison, Ennaid Therapeutics CEO

Formerly a Microbiologist and Chemist, Ms. Harrison is a nationally recognized pharmaceutical entrepreneur by Newsweek magazine. With 22 years' experience in the life sciences, she is a member of the American Association for the Advancement of Science and the New York Academy of Sciences. She received a Bachelor of Science in Microbiology and a Minor in Chemistry from LSU.

For interviews, investment or more information contact:
Gigi Gilbert, Public Relations, Phone: +404-309-7034, Email: Gigi@ennaidthera.com


'/>"/>
SOURCE Ennaid Therapeutics
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Arno Therapeutics to Present Positive, New Data Supporting the Potential of Onapristone in Endometrial and Breast Cancers at ASCO 2013 Annual Meeting
2. Novelos Therapeutics Provides Product Pipeline Update
3. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
4. PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
5. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
6. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
7. Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes
8. The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients
9. Advanced Prenatal Therapeutics - Using Targeted Apheresis to Treat Preeclampsia
10. Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML)
11. Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2019)... ... September 17, 2019 , ... Drs. Mario ... Medford, NJ, now welcome patients from Cherry Hill, NJ for tooth extractions, with ... whenever possible. When tooth removal is necessary, they use advanced equipment and techniques, ...
(Date:9/17/2019)... , ... September 17, 2019 , ... ... summit on sexual health, reproductive justice, contraception and consent with student and faculty ... by sexual health experts which included Francisco Ramirez, MPH; Elise Schuster, MPH; Raffaele ...
(Date:9/17/2019)... ... 2019 , ... Dr. Arta Farahmand welcomes patients with crooked ... to conventional orthodontics, the Wilckodontics orthodontic system often cuts treatment time by 50 ... brackets and wires that apply constant pressure on the teeth, thus causing the ...
Breaking Medicine Technology:
(Date:9/17/2019)... ... 17, 2019 , ... What if a drug that sits ... patients? In companion presentations at the American Society for Therapeutic Radiation Oncology (ASTRO) ... evidence that low-dose aspirin and other anti-inflammatories may improve survival in patients undergoing ...
(Date:9/17/2019)... ... September 17, 2019 , ... Specialty Technical Publishers (STP) and ... Protocol Consortium (IAPC) EHS audit protocol for Japan . Leading companies around ... EHS regulatory obligations and rapidly collect, share, archive, and export audit findings in ...
(Date:9/17/2019)... ... September 17, 2019 , ... CORE Medical & Wellness, ... (Jenny) Gartshteyn to their team of expert physicians. Dr. Gartshteyn completed her Rheumatology ... Appointment of Assistant Professor in Medicine for the Division of Hospitalist Medicine. , ...
(Date:9/14/2019)... ... , ... GreenTheVoteOk , one of the most reliable online resource providers ... most relevant and important developments in the fast-changing world of legalized CBD. , ... across the world suffering from different difficult-to-treat ailments, people need to identify brands that ...
(Date:9/11/2019)... ... September 11, 2019 , ... Workplace ... have struggled to solve injury risks which lead to musculoskeletal disorders (MSDs). ... solution developed by the team at Soter Analytics helps avoid ergonomic ...
Breaking Medicine News(10 mins):